Hikma Pharmaceuticals PLC

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:16 2024-04-23 am EDT			5-day change	1st Jan Change
1,819 ^GBX	+0.06%		+1.85%	+1.68%

Apr. 15	Hikma Pharmaceuticals PLC Announces Executive Changes	CI
Mar. 11	FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data	DJ

Hikma Pharmaceuticals plc Announces Company Secretary Change

June 15, 2022 at 10:00 am EDT

Hikma Pharmaceuticals PLC announces that Peter Speirs will step down as Company Secretary and Hussein Arkhagha, Chief Counsel, will take on the additional role as Company Secretary effective from 15 June 2022.

Latest news about Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC Announces Executive Changes	Apr. 15	CI
FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data	Mar. 11	DJ
The FTSE 100 Closed Up 0.4% as U.K. Announces Spring Budget Tax Cuts	Mar. 06	DJ
Rakuten Medical, Inc. announced that it has received $45 million in funding from Dai-ichi Life Holdings, Inc., Mizuho Bank, Ltd., Hikma Pharmaceuticals PLC, Rakuten Ventures, SBI Holdings, Inc., Investment Arm and another investor	Mar. 05	CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down	Mar. 03	MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals	Mar. 03	MT
AFT Pharmaceuticals Limited Extends License for Maxigesic/Combogesic IV with Hikma Pharmaceuticals	Mar. 03	CI
RBC Keeps Hikma Pharmaceuticals at Sector Perform, Raises PT	Feb. 29	MT
Barclays cuts Direct Line to equal weight	Feb. 29	AN
Stocks called up following slew of FTSE 100 earnings	Feb. 29	AN
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada	Feb. 28	MT
Merck's Bridion faces generic threat from drugmaker Hikma	Feb. 26	RE
Barclays raises Breedon but cuts Domino's Pizza	Feb. 23	AN
FTSE 100 Closes Up After Nvidia Results Lead to Global Rally	Feb. 22	DJ
HIKMA PHARMACEUTICALS : Strong Generics-led finish to 2023	Feb. 22
JPMorgan Keeps Hikma Pharmaceuticals at Overweight, Raises PT	Feb. 22	MT
Transcript : Hikma Pharmaceuticals PLC, 2023 Earnings Call, Feb 22, 2024	Feb. 22
Berenberg raises Moneysupermarket.com to 'buy'	Feb. 22	AN
Hikma boosts dividend after year of "significant progress"	Feb. 22	AN
Drugmaker Hikma expects profit to be slightly lower in 2024	Feb. 22	RE
Hikma Pharmaceuticals Reports Improved FY23 Profit, Revenue	Feb. 22	MT
Earnings Flash (HIK.L) HIKMA PHARMACEUTICALS Posts FY23 EPS $0.85	Feb. 22	MT
Hikma Pharmaceuticals PLC Provides Group Earnings Guidance for the Year 2024	Feb. 22	CI
Hikma Pharmaceuticals PLC Announces Board Changes	Feb. 22	CI
Hikma Pharmaceuticals PLC Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI

Chart Hikma Pharmaceuticals PLC

Duration

Period

More charts

Company Profile

Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Sales and Revenue Release - Trading Update

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

HIKMA PHARMACEUTICALS : Strong Generics-led finish to 2023

February 22, 2024 at 09:22 am EST

More Strategies

Ratings for Hikma Pharmaceuticals PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.63 USD

Average target price

28.85 USD

Spread / Average Target

+27.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HIKMA PHARMACEUTICALS PLC	+1.68%	4.98B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals